Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

Fig. 5

In vivo activities of compound 1 in a systemic mouse model of MV4-11 leukemia. a Treatment of NOD-SCID mice with 1 caused no significant changes in blood cell counts, suggesting no obvious toxicities. b Compound 1 (2.5 and 5 mg/kg/day for 28 days) significantly reduced MV4-11 leukemia cells in the bone marrow, spleen, and peripheral blood, with the higher dosage showing more pronounced antitumor effects (* p < 0.05 with respect to the control). c Treatment with 1 (2.5 and 5 mg/kg/day for 28 days) significantly prolonged the life span of mice transplanted with MV4-11 leukemia (p < 0.05 and 0.01, respectively). The median survivals for the control and 2.5 mg/kg treatment group were 34.5 and 43 days, respectively. The higher dosage treatment caused an increased antitumor efficacy, with the median survivals for the two groups being 45 and 60 days, respectively

Back to article page